Latest news with #LaReunion
Reuters
10 hours ago
- Health
- Reuters
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
June 9 (Reuters) - UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's ( opens new tab shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above as a precautionary measure. The vaccine, IXCHIQ, was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in February to protect people aged 18 years and above against chikungunya, but is not yet available in the UK market. "The decision to restrict the licence until further review is based on global data which has highlighted 23 cases of serious adverse reactions, including two cases reporting a fatal outcome, in people aged from 62 to 89 years of age who received the vaccine," the regulator said. The adverse events, opens new tab were reported in the French overseas territory of La Reunion, where a chikungunya outbreak was reported earlier this year. MHRA's decision comes after the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) in May suspended, opens new tab the use of the vaccine in the age group. The French Government was the first to take the step in April.
Daily Mail
11 hours ago
- Health
- Daily Mail
BREAKING NEWS UK vaccine chiefs suspend newly approved jab for over 65s - reports of two deaths and 21 severe reactions
UK vaccine chiefs have suspended a newly approved jab for over 65s after reports of two deaths and 21 severe reactions. The Chikungunya vaccine (IXCHIQ) has been temporarily paused in people aged 65 and over as a precautionary measure after two deaths. It follows global reports of serious adverse effects in older people of 23 cases of serious adverse reaction, including two deaths. The Chikungunya virus (CHIKV) is found in the subtropical regions of the Americas, Africa, Southeast Asia, India, and the Pacific Region. It is spread to humans by the bite of an infected mosquito (Aedes aegypti and Aedes albopictus)—it cannot be passed from human to human. The two deaths occurred in people aged 62 to 89 years of age who received the vaccine. There are no changes in the recommendations for vaccination with IXCHIQ for people of 18 to 64 years of age. A recent outbreak in La Reunion, an overseas department and region of France, saw over 47,500 people contract the virus, with 12 fatalities. The majority of people infected with chikungunya develop a sudden fever and severe pain in multiple joints (arthralgia).
